title: CD8+ cells in HIV infection produce macrophage inflammatory protein-1 alpha and RANTES: a comparative study in long-term survivors and progressor patients.
abstract: Evidence suggests that CD8+ lymphocytes are involved in the control of Human Immunodeficiency virus type 1 (HIV-1) infection by the release of HIV-suppressive factors. The human chemokines RANTES and the macrophage inflammatory protein 1 alpha (MIP-1 alpha) have been identified to be potent inhibitors of HIV in vitro. The aim of this study was to determine whether high levels of these chemokines are associated with a delayed progression of HIV disease. We have therefore analysed the in vitro production of RANTES and MIP-1 alpha from purified stimulated CD8+ cells from HIV+ long term survivors (LTS) and, as a comparison, from HIV+ patients with progressive disease. RANTES production was similar in LTS and progressors (14.06 +/- 3, 13.36 +/- 4.1 ng/ml, not statistically significant); the same cells from healthy controls show a RANTES production of 20 +/- 3.5 ng/ml (P = 0.034 versus LTS and P = 0.038 versus progressors). MIP-1 alpha production was slightly reduced in LTS (96.8 +/- 12 ng/ml) and progressors (91.6 + 17, not statistically significant between the two groups) when compared to healthy controls (109 +/- 7 ng/ml, P = 0.03). Our study suggests that resistance to HIV-1 progression in LTS may not be associated with high levels of RANTES and MIP-1 alpha production.
authors.affiliation: Microbiology-Immunology-Virology Division, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Zanussi
authors.forename: M
authors.initials: M
authors.lastname: D'Andrea
authors.forename: C
authors.initials: C
authors.lastname: Simonelli
authors.forename: V
authors.initials: V
authors.lastname: Battiston
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: P
authors.initials: P
authors.lastname: De Paoli
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000096:biosynthesis*; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1; D006801:Humans; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D018655:Lymphocyte Count; D019402:Macrophage Inflammatory Proteins / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017741:Survivors; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D019402:Macrophage Inflammatory Proteins; D017493:Leukocyte Common Antigens; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1